SRI hopes to hasten the development process of anticancer compounds.

SRI International received a $7.9 million contract from the NCI to conduct analytical chemistry evaluations of its anticancer drugs and dosage formulations.

“By conducting in-depth chemical analysis of promising drug candidates, we can help expedite the flow of new anticancer discoveries to the clinic,” says Jennie Wang, analytical chemistry program director in SRI’s Biosciences Division. “Analytical chemistry data can help improve the safety and consistency of drug development at all stages of research.”

SRI points out that chemical data such as identity, strength, quality, and stability of a drug provides a better definition of the substance or dosage formulation, leading to safer and more effective therapies.

Previous articleGalapagos Enters Billion-Dollar Alliance with Janssen Related to RA
Next articleGlycominds and Fox Chase Cancer Center Partner to Discover Breast Cancer Diagnostic Blood Test